Collagen and calcium-binding EGF domains 1 is frequently inactivated in ovarian cancer by aberrant promoter hypermethylation and modulates cell migration and survival

被引：37

作者：

Barton, C. A. ^{[1
]}

Gloss, B. S. ^{[1
]}

Qu, W. ^{[1
]}

Statham, A. L. ^{[1
]}

Hacker, N. F. ^{[1
,2
,3
]}

Sutherland, R. L. ^{[1
,3
]}

Clark, S. J. ^{[1
,3
]}

O'Brien, P. M. ^{[1
,3
]}

机构：

[1] St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia

[2] Royal Hosp Women, Gynaecol Canc Ctr, Randwick, NSW 2031, Australia

[3] Univ NSW, Fac Med, Sydney, NSW 2031, Australia

来源：

BRITISH JOURNAL OF CANCER | 2010年 / 102卷 / 01期

基金：

英国医学研究理事会;

关键词：

ovarian cancer; CCBE1; tumour suppressor; ASPARAGINYL-BETA-HYDROXYLASE; COMPARATIVE GENOMIC HYBRIDIZATION; GROWTH-FACTOR; GENE-EXPRESSION; HEPATOCELLULAR-CARCINOMA; VITELLOGENIN RECEPTOR; DNA METHYLATION; OVEREXPRESSION; CHOLANGIOCARCINOMA; ASSOCIATION;

D O I：

10.1038/sj.bjc.6605429

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

BACKGROUND: Collagen and calcium-binding EGF domains 1 (CCBE1) is an uncharacterised gene that has down-regulated expression in breast cancer. As CCBE1 maps to 18q21.32, a region frequently exhibiting loss of heterozygosity in ovarian cancer, the aim of this study was to determine the expression and function of CCBE1 in ovarian cancer. METHODS: Expression and methylation patterns of CCBE1 were determined in ovarian cancer cell lines and primary tumours. CCBE1 contains collagen repeats and an aspartic acid/asparagine hydroxylation/EGF-like domain, suggesting a function in extracellular matrix remodelling and migration, which was determined using small-interfering RNA (siRNA)-mediated knockdown and over-expression of CCBE1 in cell lines. RESULTS: CCBE1 is expressed in normal ovary, but is reduced in ovarian cancer cell lines and primary carcinomas. Pharmacological demethylation/deacetylation in ovarian cancer cell lines re-induced CCBE1 expression, indicating that epigenetic mechanisms contribute to its silencing in cancer. CCBE1 promoter hypermethylation was detected in 6/11 (55%) ovarian cancer cell lines and 38/81 (41%) ovarian carcinomas. siRNA-mediated knockdown of CCBE1 in ovarian cancer cell lines enhanced their migration; conversely, re-expression of CCBE1 reduced migration and survival. Hence, loss of CCBE1 expression may promote ovarian carcinogenesis by enhancing migration and cell survival. CONCLUSIONS: These data suggest that CCBE1 is a new candidate tumour suppressor in ovarian cancer. British Journal of Cancer (2010) 102, 87-96. doi:10.1038/sj.bjc.6605429 www.bjcancer.com Published online 24 November 2009 (C) 2010 Cancer Research UK

引用

页码：87 / 96

页数：10

共 39 条

[1]

Ovarian surface epithelium: Biology, endocrinology, and pathology [J].

Auersperg, N ;

Wong, AST ;

Choi, KC ;

Kang, SK ;

Leung, PCK .

ENDOCRINE REVIEWS, 2001, 22 (02) :255-288

[2]

Ovarian cancer: Changes in patterns at diagnosis and relative survival over the last three decades [J].

Barnholtz-Sloan, JS ;

Schwartz, AG ;

Qureshi, F ;

Jacques, S ;

Malone, J ;

Munkarah, AR .

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2003, 189 (04) :1120-1127

[3]

DNA methylation changes in ovarian cancer: Implications for early diagnosis, prognosis and treatment [J].

Barton, Caroline A. ;

Hacker, Neville F. ;

Clark, Susan. J. ;

O'Brien, Philippa A. .

GYNECOLOGIC ONCOLOGY, 2008, 109 (01) :129-139

[4]

Aspartyl-asparagyl β hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms [J].

Cantarini, M. Chiara ;

de la Monte, Suzanne M. ;

Pang, Maoyin ;

Tong, Ming ;

D'Errico, Antonia ;

Trevisani, Franco ;

Wands, Jack R. .

HEPATOLOGY, 2006, 44 (02) :446-457

[5]

The Secreted Protein Discovery Initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: A bioinformatics assessment [J].

Clark, HF ;

Gurney, AL ;

Abaya, E ;

Baker, K ;

Baldwin, D ;

Brush, J ;

Chen, J ;

Chow, B ;

Chui, C ;

Crowley, C ;

Currell, B ;

Deuel, B ;

Dowd, P ;

Eaton, D ;

Foster, J ;

Grimaldi, C ;

Gu, QM ;

Hass, PE ;

Heldens, S ;

Huang, A ;

Kim, HS ;

Klimowski, L ;

Jin, YS ;

Johnson, S ;

Lee, J ;

Lewis, L ;

Liao, DZ ;

Mark, M ;

Robbie, E ;

Sanchez, C ;

Schoenfeld, J ;

Seshagiri, S ;

Simmons, L ;

Singh, J ;

Smith, V ;

Stinson, J ;

Vagts, A ;

Vandlen, R ;

Watanabe, C ;

Wieand, D ;

Woods, K ;

Xie, MH ;

Yansura, D ;

Yi, S ;

Yu, GY ;

Yuan, J ;

Zhang, M ;

Zhang, ZM ;

Goddard, A ;

Wood, WI .

GENOME RESEARCH, 2003, 13 (10) :2265-2270

[6]

DNA methylation: Bisulphite modification and analysis [J].

Clark, Susan J. ;

Statham, Aaron ;

Stirzaker, Clare ;

Molloy, Peter L. ;

Frommer, Marianne .

NATURE PROTOCOLS, 2006, 1 (05) :2353-2364

[7]

Aspartyl-(asparaginyl)-β-hydroxylase regulates hepatocellular carcinoma invasiveness [J].

de la Monte, SM ;

Tamaki, S ;

Cantarini, MC ;

Ince, N ;

Wiedmann, M ;

Carter, JJ ;

Lahousse, SA ;

Califano, S ;

Maeda, T ;

Ueno, T ;

D'Errico, A ;

Trevisani, F ;

Wands, JR .

JOURNAL OF HEPATOLOGY, 2006, 44 (05) :971-983

[8]

Absence of post-translational aspartyl β-hydroxylation of epidermal growth factor domains in mice leads to developmental defects and an increased incidence of intestinal neoplasia [J].

Dinchuk, JE ;

Focht, RJ ;

Kelley, JA ;

Henderson, NL ;

Zolotarjova, NI ;

Wynn, R ;

Neff, NT ;

Link, J ;

Huber, RM ;

Burn, TC ;

Rupar, MJ ;

Cunningham, MR ;

Selling, BH ;

Ma, JH ;

Stern, AA ;

Hollis, GF ;

Stein, RB ;

Friedman, PA .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (15) :12970-12977

[9]

Aspartyl β-hydroxylase (Asph) and an evolutionarily conserved isoform of Asph missing the catalytic domain share exons with junctin [J].

Dinchuk, JE ;

Henderson, NL ;

Burn, TC ;

Huber, R ;

Ho, SP ;

Link, J ;

O'Neil, KT ;

Focht, RJ ;

Scully, MS ;

Hollis, JM ;

Hollis, GF ;

Friedman, PA .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (50) :39543-39554

[10]

New functions for the matrix metalloproteinases in cancer progression [J].

Egeblad, M ;

Werb, Z .

NATURE REVIEWS CANCER, 2002, 2 (03) :161-174

← 1 2 3 4 →